Company news
Citius Pharmaceuticals, Inc. news in 2026
Citius Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
November 4, 2026
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
October 26, 2026
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
October 12, 2026
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
September 3, 2026
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
August 12, 2026
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
August 5, 2026
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
July 21, 2026
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
May 31, 2026
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
May 26, 2026
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
May 15, 2026
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
April 29, 2026
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
April 27, 2026
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
April 24, 2026
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
March 31, 2026
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
March 24, 2026
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
March 9, 2026
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
March 3, 2026
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
February 23, 2026
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
February 16, 2026
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
February 10, 2026